2. Signaling Pathways
  3. TGF-beta/Smad
  4. TGF-β Receptor
  5. ALK7 Isoform

ALK7

ALK7 (ACVR1C) is a human type I receptor serine/threonine kinase in the TGF-β receptor system[1]. Mechanistically, activin isoforms signal through ALK7, and activin C activates SMAD2/3 signaling through ALK7 in differentiated adipocytes[2][3]. In pancreatic islets, activin B receptor ALK7 negatively regulates β-cell function, and ALK7 activation induces pancreatic β-cell apoptosis through Akt suppression and the SMAD2-caspase-3 cascade[4][5]. In adipose models, GDF3-ALK7 signaling regulates adipose-tissue homeostasis under nutrient overload, while ALK7 dysfunction increases lipolysis and reduces fat accumulation[6][7]. In cancer models, ALK7 signaling functions as a suppressive tissue barrier to tumorigenesis and metastasis, and activin B-ALK7 activation induces apoptosis in neoplastic cells[8]. Compared with related isoforms, placental ALK7 transcripts include full-length, truncated, and soluble variants generated by alternative splicing, which distinguishes receptor-bound signaling from potential soluble or truncated forms[9]. For experimental applications, SB-431542 inhibits the highly related ALK4, ALK5, and ALK7 kinases, so it supports pathway blockade but does not isolate ALK7-specific biology[10].- ALK7 links activin-family signaling to SMAD2/3, β-cell regulation, adipose lipid metabolism, and apoptosis.- SB-431542 blocks ALK4/5/7 together, requiring isoform-aware controls in ALK7-focused experiments.

References:

Cat. No. Product Name Effect Purity
  • HY-10431
    SB-431542
    		Inhibitor 99.85%
    SB-431542 is a TGF-β receptor kinase inhibitor (TRKI). SB-431542 has inhibitory activity for ALK4, ALK5 and ALK7 with IC50 values of 1 μM, 0.75 μM and 2 μM, respectively. SB-431542 also inhibits TGF-β-induced transcription, gene expression, apoptosis, and growth suppression. SB-431542 can be used for the research of cancer and signal transduction pathways.
  • HY-10432
    A 83-01
    		Inhibitor 99.41%
    A 83-01 is a potent inhibitor of TGF-β type I receptor ALK5 kinase, type I nodal receptor ALK4 and type I nodal receptor ALK7, with IC50s of 12 nM, 45 nM and 7.5 nM against the transcription induced by ALK5, ALK4 and ALK7, respectively.
  • HY-10432A
    A 83-01 sodium
    		Inhibitor 98.03%
    A 83-01 sodium is a potent inhibitor of TGF-β type I receptor ALK5 kinase, ALK4 and ALK7, with IC50s of 12 nM, 45 nM and 7.5 nM against the transcription induced by ALK5, ALK4 and ALK7, respectively.
  • HY-10431G
    SB-431542 (GMP)
    		Inhibitor
    SB-431542 (GMP) is SB-431542 (HY-10431) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. SB-431542 is a TGF-β receptor kinase inhibitor (TRKI) in SMAD signaling.
  • HY-122856
    AZ12601011
    		Inhibitor 99.78%
    AZ12601011 is an orally active, selective TGFBR1 kinase inhibitor with an IC50 of 18 nM and a Kd of 2.9 nM. AZ12601011 inhibits phosphorylation of SMAD2 via selectively inhibiting ALK4, TGFBR1, and ALK7. AZ12601011 inhibits mammary tumor growth .
  • HY-185430
    HM-279
    		Inhibitor
    HM-279 is a potent and orally active ALK5 inhibitor with an IC50 of 4.7 nM. HM-279 shows cross-reactivity with ALK7 (IC50 = 6.8 nM), but HM-279 has fair to good selectivity against other TGF-β receptor family kinases, with 4.5-693-fold selectivity. HM-279 demonstrates antitumor activity in vivo through CD8+ T cell immunity. HM-279 can be used for the research of colon cancer.
  • HY-10432R
    A 83-01 (Standard)
    		Inhibitor
    A 83-01 (Standard) is the analytical standard of A 83-01 (HY-10432). This product is intended for research and analytical applications. A 83-01 is a potent inhibitor of TGF-β type I receptor ALK5 kinase, type I nodal receptor ALK4 and type I nodal receptor ALK7, with IC50s of 12 nM, 45 nM and 7.5 nM against the transcription induced by ALK5, ALK4 and ALK7, respectively.
Cat. No. Product Name / Synonyms Species Source